NASDAQ$CRBU
Caribou Biosciences Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2022 and provided a business update.
Caribou Biosciences reported financial results for the second quarter of 2022, highlighting a strong financial position with $366.1 million in cash, cash equivalents, and marketable securities. The company made significant progress in advancing its pipeline of genome-edited allogeneic CAR-T and CAR-NK cell therapies, including encouraging initial clinical data from the Phase 1 ANTLER trial for CB-010.
- Reported 6-month complete response (CR) in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial.
- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial.
- CB-011 IND submission planned for Q4 2022 in patients with r/r MM.
- CB-012 on track for 2023 IND submission in patients with r/r AML.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$4.19M
Revenue by segment
Caribou Biosciences · $4.2M total across 1 segment · Q2 2022
- Licensing & collaboration$4.2M+184.6%100.0%
Forward guidance
Caribou Biosciences anticipates several milestones for 2022 and beyond, including sharing additional data from cohort 1 of the ANTLER Phase 1 trial for CB-010 by YE 2022, submitting an IND application for CB-011 in Q4 2022, announcing target selection for CB-020 in Q4 2022, and submitting an IND application for CB-012 in 2023.
Tailwinds
- Plans to share additional data from cohort 1 of the ongoing ANTLER Phase 1 trial for CB-010 by YE 2022.
- Expects to submit an IND application for CB-011 in Q4 2022.
- Expects to announce target selection for CB-020 in Q4 2022.
- Expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022.
- Expects to submit an IND application for CB-012 in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro